Search results
Psoriasis study shows high level of arthritis symptoms in patients
Medical Xpress· 4 days agoThe study led by researchers at the Universities of Oxford, University College Dublin and supported...
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the...
The Woonsocket Call· 2 days agoJohnson & Johnson (NYSE: JNJ) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of TREMFYA ...
Polycystic Ovarian Syndrome: New Science Offers Old Remedy
Medscape· 4 days agoAn ancient Chinese remedy for malaria could offer new hope to the 10% of reproductive-age women...
How AI Is Revolutionizing Drug Development
The New York Times via Yahoo News· 5 days agoMONROVIA, Calif. — The laboratory at Terray Therapeutics is a symphony of miniaturized automation. Robots whir, shuttling tiny tubes of fluids to their...
States struggle to help patients navigate insurance hurdle known as ‘step therapy’
Missouri Independent via Yahoo News· 5 days agoCassidy Yermal, 32, began experiencing debilitating migraines when she was 17 years old. As a...
Why Is My Skin So Itchy?
Verywell Health via Yahoo News· 4 days agoPruritus, or itchy skin, is a characteristic feature of many skin diseases and an unusual sign of some systemic diseases. It can be painful or...
Drug names: How companies and regulators come up with hundreds of new names every year
Quartz· 3 days agoEverything you need to know about the art and science of drug naming in five minutes or less,...
In a 'gold rush' for treating bowel disease, AbbVie clears one more stage
Crain s Chicago Business· 3 days agoWith the arrival of biosimilar competition for its blockbuster drug Humira, AbbVie has said much of its sales growth potential lies with these two anti-inflammatories. In April, the North Chicago ...
How Neuroscience Is Leading the Next Wave of Skin-Care Innovation
PopSugar· 2 days agoNot to mention, aromatherapy uses scent to affect mood and CBD products bind to cannabinoid...
U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio...
Morningstar· 3 days agoApproval supported by two Phase 3 clinical trials that evaluated SKYRIZI® for the treatment of moderate to severe ulcerative colitis: a 12-week induction study, INSPIRE,1 and a 52-week maintenance study, COMMAND2Data showed that clinical remission,